Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riferminogene pecaplasmid in Critical Limb Ischemia
NCT00566657Phase 3Completed
- Sponsor
- Sanofi
- Start
- Nov 2007
- Primary completion
- Aug 2010
- Modality
- Gene Editing, Gene Silencing, Fc-Fusion Proteins
- Countries
- 32
01
Overview
A Phase 3 trial of Riferminogene pecaplasmid in critical limb ischemia (CLI), sponsored by Sanofi. Started Nov 2007; status: completed.
02
Drugs
Riferminogene pecaplasmid
03
Conditions
critical limb ischemia (CLI)
Beyond the preview
Go deeper on NCT00566657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00566657.